Testing linvoseltamab for AL amyloidosis that came back
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called linvoseltamab for people with AL amyloidosis that has returned or is not responding to treatment. It aims to see if the drug is safe and helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AL amyloidosis.
- Your disease has come back or hasn't responded well to at least one prior treatment.
- Your heart function is stable, with a specific blood test (NT-proBNP) level at 8500 ng/L or lower.
- You have measurable levels of abnormal light chains in your blood.
- You are generally well enough to carry out daily activities (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
This trial tests a combination of two drugs (linvoseltamab and tocilizumab) for adults with multiple myeloma that has stopped responding to standard treatments. Tocilizumab is added to help reduce serious side effects from the main drug.
This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.
This study tests a new combination of two drugs (REGN7945 and linvoseltamab) for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if the combination is safe and effective, and it may offer a new option if other therapies have stopped working.
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
Hear when a new Relapsed/Refractory Systemic Light Chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.